XING

Cover Image

CRS Clinical Research Services Neuigkeiten

CRS Clinical Research Services
CRS Clinical Research Serviceshat einen Beitrag geschrieben22. März
CRS eröffnet ein neues Kapitel mit der Ernennung von Elisabeth Lackner, einer führenden Branchenexpertin, zur Geschäftsführerin: Wir freuen uns, Dr. Elisabeth Lackner als neue Geschäftsführerin von CRS Clinical Research Services seit dem 15. März 2024 bekannt zu geben. Herzlich willkommen, @Elisabeth Lackner! Frau Dr. Lackner ist mit der Leitung der zukünftigen strategischen Ausrichtung des Unternehmens betraut und wird die Internationalisierung des Unternehmens vorantreiben und das Dienstleistu...
Posting image
CRS Clinical Research Services
CRS Clinical Research Serviceshat einen Beitrag geschrieben8. Februar
🎉 We are pleased to announce that CRS Clinical Research Services is now a member of InnoNet HealthEconomy e.V. As part of this dynamic network, we connect with the most innovative players in the healthcare industry in Rhineland-Palatinate and neighboring regions. 🤝 Our aim is to promote interaction between politics, healthcare and business and to work together on forward-looking solutions. We look forward to being part of this collaboration and to the exciting opportunities that membership o...
Posting image
CRS Clinical Research Services
CRS Clinical Research Serviceshat einen Beitrag geschrieben1. Februar
Have you already read this interesting publication on Journal of Diabetes & Metabolic Disorders? 📑 📢 Check out the study “Non alcoholic fatty liver disease in obese subjects as related to increasing insulin resistance and deteriorating glucose control: Three years of follow up from a longitudinal survey” to delve into the key findings and implications. We congratulate the team for their hard work and dedication! Read the publication here: https://link.springer.com/article/10.1007/s40200-023-0 ...

Non-alcoholic fatty liver disease in obese subjects as related to increasing insulin resistance and deteriorating glucose control: Three years of follow-up from a longitudinal survey - Journal of Diabetes & Metabolic Disorders

Purpose This observational trial was performed to evaluate liver parameters in overweight or obese subjects in the context of insulin resistance and glucose control over time. Subjects/Methods Insulin resistance, glucose control and several parameters for liver integrity were monitored in 177 overweight (BMI > 28 kg/m2) subjects over a mean of 30 months. Volunteers were categorized according to insulin resistance (HOMAIR score) and glucose control in subjects with normal glucose control (NGT), impaired glucose control (IGT), or diabetes mellitus type 2 (T2DM). Liver fat and fibrosis were evaluated by sonographic elastography (FibroScan®) and clinical scores, such as the AST/ALT ratio, fatty liver index (FLI), and NAFLD fibrosis score (NFS). Results Liver fat fraction as estimated by the controlled attenuation parameter (CAP), and the FLI were significantly higher in subjects with T2DM compared to IGT and NGT. While fasting insulin levels and the HOMAIR score continuously increased over time, no change in CAP or FLI occurred during follow up. CAP was correlated with FLI (r = 0.50; p < 0.0001) and the HOMAIR score (r = 0.32; p < 0.0001). An inverse correlation was observed between serum adiponectin levels and FLI (r = -0.37; p < 0.0001), the HOMAIR score (r = -0.19; p < 0.001, and CAP (r = -0.15; p < 0.01). Conclusions In subjects with a BMI ≥ 28 kg/m2, liver fat fraction is significantly elevated in those with T2DM compared to IGT or NGT. Liver fat fraction is associated with deteriorating insulin sensitivity and loss of glucose control. Despite a continuous increase in insulin resistance, no change in liver fat content or stiffness occurred over 30 months.link.springer.com
Non-alcoholic fatty liver disease in obese subjects as related to increasing insulin resistance and deteriorating glucose control: Three years of follow-up from a longitudinal survey - Journal of Diabetes & Metabolic Disorders